vs
NRX Pharmaceuticals, Inc.（NRXP）与瑞图生态（RETO）财务数据对比。点击上方公司名可切换其他公司
瑞图生态的季度营收约是NRX Pharmaceuticals, Inc.的1.1倍（$1.0M vs $983.0K），NRX Pharmaceuticals, Inc.净利率更高（36.7% vs -131.6%，领先168.3%）
NRX Pharmaceuticals是一家处于临床阶段的生物制药企业，专注于开发针对中枢神经系统疾病的创新疗法，覆盖罕见神经精神类适应症，核心市场以美国为主，核心在研产品面向有未满足医疗需求的重度情绪与创伤相关疾病患者。
瑞图生态是一家专业环保解决方案提供商，主营环保建筑材料研发生产、生态修复服务及固体废弃物处理方案，核心产品包含再生建筑骨料、土壤改良制剂等，主要服务中国市场的基建、地产及生态修复领域。
NRXP vs RETO — 直观对比
营收规模更大
RETO
是对方的1.1倍
$983.0K
净利率更高
NRXP
高出168.3%
-131.6%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $983.0K | $1.0M |
| 净利润 | $361.0K | $-1.4M |
| 毛利率 | — | 17.7% |
| 营业利润率 | — | -133.0% |
| 净利率 | 36.7% | -131.6% |
| 营收同比 | — | 36.6% |
| 净利润同比 | 104.0% | -103.5% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRXPRETO
| Q4 25 | $983.0K | — | ||
| Q3 25 | $242.0K | — | ||
| Q2 25 | $0 | $1.0M | ||
| Q1 25 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | — | $768.4K | ||
| Q2 22 | — | $2.9M |
净利润NRXPRETO
| Q4 25 | $361.0K | — | ||
| Q3 25 | $-5.9M | — | ||
| Q2 25 | $-17.6M | $-1.4M | ||
| Q1 25 | $-5.5M | — | ||
| Q3 24 | $-1.6M | — | ||
| Q2 24 | — | $-678.5K | ||
| Q2 22 | — | $-5.7M |
毛利率NRXPRETO
| Q4 25 | — | — | ||
| Q3 25 | 59.9% | — | ||
| Q2 25 | — | 17.7% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 43.3% | ||
| Q2 22 | — | 13.0% |
营业利润率NRXPRETO
| Q4 25 | — | — | ||
| Q3 25 | -1662.8% | — | ||
| Q2 25 | — | -133.0% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -68.0% | ||
| Q2 22 | — | -195.8% |
净利率NRXPRETO
| Q4 25 | 36.7% | — | ||
| Q3 25 | -2433.9% | — | ||
| Q2 25 | — | -131.6% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -88.3% | ||
| Q2 22 | — | -196.4% |
每股收益（稀释后）NRXPRETO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-0.25 | ||
| Q2 22 | — | $-0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.8M | $2.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-15.9M | $30.4M |
| 总资产 | $13.0M | $41.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRXPRETO
| Q4 25 | $7.8M | — | ||
| Q3 25 | $7.2M | — | ||
| Q2 25 | $2.9M | $2.5M | ||
| Q1 25 | $5.5M | — | ||
| Q3 24 | $1.6M | — | ||
| Q2 24 | — | $1.6M | ||
| Q2 22 | — | $832.4K |
股东权益NRXPRETO
| Q4 25 | $-15.9M | — | ||
| Q3 25 | $-25.8M | — | ||
| Q2 25 | $-35.6M | $30.4M | ||
| Q1 25 | $-25.2M | — | ||
| Q3 24 | $-18.8M | — | ||
| Q2 24 | — | $13.3M | ||
| Q2 22 | — | $13.5M |
总资产NRXPRETO
| Q4 25 | $13.0M | — | ||
| Q3 25 | $15.0M | — | ||
| Q2 25 | $4.8M | $41.4M | ||
| Q1 25 | $7.6M | — | ||
| Q3 24 | $4.5M | — | ||
| Q2 24 | — | $33.7M | ||
| Q2 22 | — | $33.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.7M | $-1.6M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.7M |
| 自由现金流率自由现金流/营收 | — | -157.4% |
| 资本支出强度资本支出/营收 | — | 5.1% |
| 现金转化率经营现金流/净利润 | -10.29× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流NRXPRETO
| Q4 25 | $-3.7M | — | ||
| Q3 25 | $-2.9M | — | ||
| Q2 25 | $-4.0M | $-1.6M | ||
| Q1 25 | $-3.5M | — | ||
| Q3 24 | $-2.3M | — | ||
| Q2 24 | — | $-4.8M | ||
| Q2 22 | — | $-9.3M |
自由现金流NRXPRETO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.7M | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | — |
自由现金流率NRXPRETO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -157.4% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | — |
资本支出强度NRXPRETO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | — |
现金转化率NRXPRETO
| Q4 25 | -10.29× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
